Evelo Biosciences, Inc. (EVLO)
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Address
124 WASHINGTON STREET, SUITE 101
FOXBORO, MA 02035
Founded
2014
Number of Employees
-
Website
http://www.evelobio.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)